An interventional study of Dipeptidyl peptidase 4 (DPP 4) inhibitor and oral glucose in Vagotomy, Truncal, sponsored by University Hospital, Gentofte, Copenhagen. Status unknown at 1 site in Denmark. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-12-07.
Sponsored by University Hospital, Gentofte, Copenhagen · Not applicable, Interventional, and Basic science
The aim of this study is to investigate the role of transmission via the vagal nerve for the effect of glucose and Glucagon-like peptide-1 (GLP-1) in respect to insulin secretion.
The hypothesis is that a great deal of the effects of GLP-1 is mediated via the nervous system and for this reason the investigators will research individuals with and without intact nervous supply.
GLP-1 is a potent enterogastron and incretin hormone. It is rapidly inactivated by dipeptidyl peptidase IV so only 10-15% enters the systemic circulation. This has led to the hypothesis that GLP-1 interact locally with afferent sensory nerve fibers. We investigated the role of intact vagal innervations on the effect of glucose and GLP-1 on the insulin secretion
University Hospital, Gentofte, Copenhagen is the lead sponsor of 154 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Truncally vagotomized subjects (due to duodenal ulcer operation)
Drug: Dipeptidyl peptidase 4 (DPP 4) inhibitor · Other: oral glucose
Truncally vagotomized subjects (due to cardia resection)
Drug: Dipeptidyl peptidase 4 (DPP 4) inhibitor · Other: oral glucose
Healthy matched control subjects
Drug: Dipeptidyl peptidase 4 (DPP 4) inhibitor · Other: oral glucose
One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
Also known as: Galvus
50 g glucose dissolved in 300 ml water with 1,5 g paracetamol is to be ingested orally within the first 15 minutes.
Also known as: panodil
insulin secretion
The insulin secretion during a four-hour oral glucose tolerance test (OGTT) and an intravenous isoglycaemic clamp is evaluated
Time frame: four hours
plasma GLP-1
12 blood samples will be drawn during the four hours OGTT and intravenous isoglycaemic clamp, most frequently during the first hour
Time frame: 12 time points within four hours
plasma GIP
12 blood samples will be drawn during the four hours OGTT and intravenous isoglycaemic clamp, most frequently during the first hour
Time frame: 12 time points within four hours
plasma glucagon
12 blood samples will be drawn during the four hours OGTT and intravenous isoglycaemic clamp, most frequently during the first hour
Time frame: 12 time points within four hours
plasma GLP-2
12 blood samples will be drawn during the four hours OGTT and intravenous isoglycaemic clamp, most frequently during the first hour
Time frame: 12 time points within four hours
plasma PYY
12 blood samples will be drawn during the four hours OGTT and intravenous isoglycaemic clamp, most frequently during the first hour
Time frame: 12 time points within four hours
This study is status unknown, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Gentofte, Copenhagen